Valeant Issues Statement On Sales Of Company Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- S&P 500, Dow rise on Mideast deal hopes, SpaceX's historic debut
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil nears two-month lows on reports of imminent US-Iran peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- BofA lifts targets on AMD and ARM, raises CPU TAM to $170bn
Valeant Pharma (VRX) Sees 'Dead Cat Bounce' after CEO Hit with Margin Call
November 6, 2015 12:19 PM ESTValeant Pharma (NYSE: VRX) is pushing to the highs of the session, following earlier news that about 1.3 million shares CEO Mike Pearson had pledged on a loan were sold yesterday due to margins calls.
The news suggests that some of the... More
Valeant Pharma (VRX) 1.3M Shares Pledged on Behalf of Pearson Sold by Goldman Sachs
November 6, 2015 8:03 AM ESTValeant Pharmaceuticals International, Inc. (NYSE: VRX) stated today that 1,297,399 shares pledged to Goldman Sachs to secure loans made to chairman and chief executive officer J. Michael Pearson were sold by Goldman Sachs on November 5, 2015. Goldman Sachs held the shares as collateral for loans extended to Pearson.
As disclosed in the company's proxy statement filed on April 22, 2014, the company's board permitted... More
